Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP1 | P03956 | 1/20 | 0.41 |
| ▸ | MMP3 | P08254 | 1/20 | 0.41 |
| ▸ | MMP7 | P09237 | 1/20 | 0.41 |
| ▸ | TAAR1 | Q96RJ0 | 6/20 | 0.40 |
| ▸ | TBXAS1 | P24557 | 2/20 | 0.39 |
| ▸ | FNTA | P49354 | 1/20 | 0.37 |
| ▸ | FNTB | P49356 | 1/20 | 0.37 |
| ▸ | PGGT1B | P53609 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | TERT | O14746 | 1/20 | 0.36 |
| ▸ | FPR2 | P25090 | 1/20 | 0.35 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27122522 | 1.00 | MMP1 (0.41) | MMP1MMP3MMP7TAAR1TBXAS1 | |
| SCHEMBL3684536 | 0.82 | TBXAS1 (0.43) | MMP1MMP3MMP7TAAR1TBXAS1 | |
| SCHEMBL24387814 | 0.82 | AAK1 (0.46) | GAA | |
| SCHEMBL27128098 | 0.77 | PLA2G10 (0.33) | SMN1; SMN2 | |
| SCHEMBL26965372 | 0.77 | PLA2G10 (0.33) | SMN1; SMN2 | |
| SCHEMBL26965342 | 0.77 | LMNA (0.43) | GAASMN1; SMN2HRH4 | |
| SCHEMBL27127864 | 0.77 | LMNA (0.43) | GAASMN1; SMN2HRH4 | |
| SCHEMBL19859837 | 0.74 | NAMPT (0.44) | TAAR1TBXAS1GAASMN1; SMN2FPR2 | |
| SCHEMBL7459376 | 0.72 | FDPS (0.41) | TAAR1TBXAS1GAASMN1; SMN2TERT | |
| SCHEMBL233107 | 0.72 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230406860-A1 | HETEROCYCLIC SPIRO COMPOUNDS AND METHODS OF USE | AMGEN INC. | 2023-12-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230406860-A1 | HETEROCYCLIC SPIRO COMPOUNDS AND METHODS OF USE | KRAS, NRAS, HRAS | MMP1 4569/4885MMP3 4108/4885MMP7 4127/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.